山东华特达因健康股份有限公司 关于子公司达因药业获得药品注册证书的公告

Core Viewpoint - The announcement highlights that Shandong Huate Dain Health Co., Ltd.'s subsidiary, Dain Pharmaceutical, has received a drug registration certificate for a medication aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-17, which is expected to enhance the company's product pipeline and competitive position in the pediatric health sector [1][2]. Group 1: Drug Registration Certificate Details - Dain Pharmaceutical has obtained the drug registration certificate for Clonidine Hydrochloride Extended-Release Tablets, with the certificate number 2025S03966 [1]. - The medication is intended for the treatment of ADHD in children and adolescents aged 6-17, either alone or as an adjunct to central nervous system stimulants [1]. Group 2: Impact on the Company - The acquisition of the drug registration certificate is anticipated to enrich the company's product line in the ADHD treatment area, supporting the realization of its strategic development and enhancing its competitiveness [2]. - The introduction of this medication is expected to positively impact the company's commitment to children's health and its performance [2].